Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1049
Title: Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
Epworth Authors: Murphy, Declan
Lawrentschuk, Nathan
Other Authors: Hofman, Michael
Maurer, Tobias
Keywords: Prostate Cancer
Ga-labelled Prostate-Specific Membrane Antigen
Positron-Emission Tomography
PET Scanning
CT
PSMA Scanning
Biochemical Recurrence
BCR
Radical Prostatectomy
Pelvic Lymph Node
Neoplasms
Pathology
Lymph Node Metastasis
PSA
Epworth Prostate Cancer Research Centre, Epworth HealthCare, Victoria, Australia
Cancer Services Clinical Institute, Epworth Healthcare, Victoria, Australia
Issue Date: Feb-2017
Publisher: Wiley Online Library
Citation: BJU Int. 2017 Feb;119(2):194-195
Abstract: The use of 68Ga-labelled prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/CT for staging prostate cancer in Australia has reached almost plague-like proportions. Despite what must be admitted is little high-level evidence to guide us in the accuracy or appropriateness of this imaging technique for either primary staging or prostate cancer recurrence, hundreds of these scans are being performed every week around Australia, and in many cases we simply do not know what to do with the results. We performed the first such scan at our centre in Melbourne in August 2014, and were soon receiving 10 requests per day, with patients waiting up to 3 months to be scanned. Fast-forward 2 years, and there are now eight centres offering PSMA PET/CT in Melbourne, a city of 4.5 million people. Scans can be obtained within 24 h of referral and costs have dropped to €500. A similar situation exists in Germany where this imaging method was pioneered, and interest is also growing in Belgium, Italy, India and a number of other countries (the USA being a notable exception). But do we really understand the impact of the decision to perform PSMA/PET scanning, and do we have enough evidence to guide us on the most appropriate setting for its use?
URI: http://hdl.handle.net/11434/1049
DOI: 10.1111/bju.13600
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28090758
ISSN: 1464-410X
Journal Title: BJU International
Type: Journal Article
Affiliated Organisations: Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Vic., Australia.
Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Department of Surgery, The Austin Hospital, University of Melbourne, Heidelberg, Vic., Australia.
Department of Urology, Technische Universitat Munchen, Klinikum rechts der Isar, Munich, Germany.
Type of Clinical Study or Trial: Narrative Reviews
Appears in Collections:Cancer Services
Epworth Prostate Centre
UroRenal, Vascular
Diagnostic Services

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.